{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:09:43Z","timestamp":1789765783408,"version":"4.0.1"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific Research Program of Hubei Provincial Department of Education","award":["B2023238"],"award-info":[{"award-number":["B2023238"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203285"],"award-info":[{"award-number":["82203285"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["242102310323"],"award-info":[{"award-number":["242102310323"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-025-05405-w","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:46:35Z","timestamp":1760370395000},"page":"127-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Crosstalk between tumor-associated macrophages and the B7\/CD28 family in immune checkpoint inhibitor-induced immunotherapy"],"prefix":"10.1007","volume":"481","author":[{"given":"Rui","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"Suppl 1","key":"5405_CR1","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1002\/eji.200737638","volume":"37","author":"S Gordon","year":"2007","unstructured":"Gordon S (2007) The macrophage: past, present and future. Eur J Immunol 37(Suppl 1):S9\u2013S17","journal-title":"Eur J Immunol"},{"key":"5405_CR2","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam A, Mohammadian S, Vazini H et al (2018) Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol 233:6425\u20136440","journal-title":"J Cell Physiol"},{"key":"5405_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nri3073","volume":"11","author":"PJ Murray","year":"2011","unstructured":"Murray PJ, Wynn TA (2011) Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11:723\u2013737","journal-title":"Nat Rev Immunol"},{"key":"5405_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1172\/JCI59643","volume":"122","author":"A Sica","year":"2012","unstructured":"Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787\u2013795","journal-title":"J Clin Invest"},{"key":"5405_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173090","volume":"877","author":"C Yunna","year":"2020","unstructured":"Yunna C, Mengru H, Lei W et al (2020) Macrophage M1\/M2 polarization. Eur J Pharmacol 877:173090","journal-title":"Eur J Pharmacol"},{"key":"5405_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A et al (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14:399\u2013416","journal-title":"Nat Rev Clin Oncol"},{"key":"5405_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","volume":"27","author":"B Ruffell","year":"2015","unstructured":"Ruffell B, Coussens LM (2015) Macrophages and therapeutic resistance in cancer. Cancer Cell 27:462\u2013472","journal-title":"Cancer Cell"},{"key":"5405_CR8","doi-asserted-by":"publisher","first-page":"8203","DOI":"10.2174\/0929867328666210720143721","volume":"28","author":"S Dallavalasa","year":"2021","unstructured":"Dallavalasa S, Beeraka NM, Basavaraju CG et al (2021) The role of tumor associated macrophages (TAMs) in cancer progression, chemoresistance, angiogenesis and metastasis - current status. Curr Med Chem 28:8203\u20138236","journal-title":"Curr Med Chem"},{"key":"5405_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A et al (2022) Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 20:44","journal-title":"Cell Commun Signal"},{"key":"5405_CR10","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41423-023-01019-8","volume":"20","author":"MC Pulanco","year":"2023","unstructured":"Pulanco MC, Madsen AT, Tanwar A et al (2023) Recent advancements in the B7\/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. Cell Mol Immunol 20:694\u2013713","journal-title":"Cell Mol Immunol"},{"key":"5405_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3389\/fimmu.2020.00681","volume":"11","author":"C Wang","year":"2020","unstructured":"Wang C, Feng H, Cheng X et al (2020) Potential therapeutic targets of B7 family in colorectal cancer. Front Immunol 11:681","journal-title":"Front Immunol"},{"key":"5405_CR12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1158\/1535-7163.MCT-16-0761","volume":"16","author":"L Ni","year":"2017","unstructured":"Ni L, Dong C (2017) New B7 family checkpoints in human cancers. Mol Cancer Ther 16:1203\u20131211","journal-title":"Mol Cancer Ther"},{"key":"5405_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01725-x","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Liu L, Liu J et al (2023) Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer 22:58","journal-title":"Mol Cancer"},{"key":"5405_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fphar.2020.00441","volume":"11","author":"L Chocarro de Erauso","year":"2020","unstructured":"Chocarro de Erauso L, Zuazo M, Arasanz H et al (2020) Resistance to PD-L1\/PD-1 blockade immunotherapy. A tumor-intrinsic or tumor-extrinsic phenomenon? Front Pharmacol 11:441","journal-title":"Front Pharmacol"},{"key":"5405_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon D, Schoenfeld AJ, Ye D et al (2024) Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell 42:209\u2013224","journal-title":"Cancer Cell"},{"key":"5405_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.semcancer.2019.12.019","volume":"65","author":"S Gomez","year":"2020","unstructured":"Gomez S, Tabernacki T, Kobyra J et al (2020) Combining epigenetic and immune therapy to overcome cancer resistance. Semin Cancer Biol 65:99\u2013113","journal-title":"Semin Cancer Biol"},{"key":"5405_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/cancers14020440","volume":"14","author":"C Martori","year":"2022","unstructured":"Martori C, Sanchez-Moral L, Paul T et al (2022) Macrophages as a therapeutic target in metastatic prostate cancer: a way to overcome immunotherapy resistance? Cancers 14:440","journal-title":"Cancers"},{"key":"5405_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/cells9010046","volume":"9","author":"C Anfray","year":"2019","unstructured":"Anfray C, Ummarino A, Andon FT et al (2019) Current strategies to target tumor-associated-macrophages to improve anti-tumor immune responses. Cells 9:46","journal-title":"Cells"},{"key":"5405_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW et al (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545:495\u2013499","journal-title":"Nature"},{"key":"5405_CR20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/cells8070747","volume":"8","author":"V Quaranta","year":"2019","unstructured":"Quaranta V, Schmid MC (2019) Macrophage-mediated subversion of anti-tumour immunity. Cells 8:747","journal-title":"Cells"},{"key":"5405_CR21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1084\/jem.20050930","volume":"203","author":"I Kryczek","year":"2006","unstructured":"Kryczek I, Zou L, Rodriguez P et al (2006) B7\u2013H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203:871\u2013881","journal-title":"J Exp Med"},{"key":"5405_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/imr.12525","volume":"276","author":"EC Nowak","year":"2017","unstructured":"Nowak EC, Lines JL, Varn FS et al (2017) Immunoregulatory functions of VISTA. Immunol Rev 276:66\u201379","journal-title":"Immunol Rev"},{"key":"5405_CR23","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","volume":"81","author":"NR Anderson","year":"2021","unstructured":"Anderson NR, Minutolo NG, Gill S et al (2021) Macrophage-based approaches for cancer immunotherapy. Cancer Res 81:1201\u20131208","journal-title":"Cancer Res"},{"key":"5405_CR24","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.3390\/cells10113194","volume":"10","author":"K Kashfi","year":"2021","unstructured":"Kashfi K, Kannikal J, Nath N (2021) Macrophage reprogramming and cancer therapeutics: role of iNOS-derived NO. Cells 10:3194","journal-title":"Cells"},{"key":"5405_CR25","doi-asserted-by":"publisher","first-page":"1264774","DOI":"10.3389\/fimmu.2023.1264774","volume":"14","author":"J Wang","year":"2023","unstructured":"Wang J, Zhu N, Su X et al (2023) Novel tumor-associated macrophage populations and subpopulations by single cell RNA sequencing. Front Immunol 14:1264774","journal-title":"Front Immunol"},{"key":"5405_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/molecules24010009","volume":"24","author":"FJ van Dalen","year":"2018","unstructured":"van Dalen FJ, van Stevendaal M, Fennemann FL et al (2018) Molecular repolarisation of tumour-associated macrophages. Molecules 24:9","journal-title":"Molecules"},{"key":"5405_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202403044","volume":"11","author":"CJ Zhang","year":"2024","unstructured":"Zhang CJ, Li JM, Xu D et al (2024) Surface molecularly engineered mitochondria conduct immunophenotype repolarization of tumor-associated macrophages to potentiate cancer immunotherapy. Adv Sci 11:e2403044","journal-title":"Adv Sci"},{"key":"5405_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874589","volume":"13","author":"Y Pu","year":"2022","unstructured":"Pu Y, Ji Q (2022) Tumor-associated macrophages regulate PD-1\/PD-L1 immunosuppression. Front Immunol 13:874589","journal-title":"Front Immunol"},{"key":"5405_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690869","volume":"12","author":"H Cai","year":"2021","unstructured":"Cai H, Zhang Y, Wang J et al (2021) Defects in macrophage reprogramming in cancer therapy: the negative impact of PD-L1\/PD-1. Front Immunol 12:690869","journal-title":"Front Immunol"},{"key":"5405_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang X, Wang J, Lu D et al (2021) Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther 6:75","journal-title":"Signal Transduct Target Ther"},{"key":"5405_CR31","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.ccell.2023.10.007","volume":"41","author":"JC Osorio","year":"2023","unstructured":"Osorio JC, Smith P, Knorr DA et al (2023) The antitumor activities of anti-CD47 antibodies require Fc-FcgammaR interactions. Cancer Cell 41:2051\u20132065","journal-title":"Cancer Cell"},{"key":"5405_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","volume":"131","author":"JH Rannikko","year":"2024","unstructured":"Rannikko JH, Hollmen M (2024) Clinical landscape of macrophage-reprogramming cancer immunotherapies. Br J Cancer 131:627\u2013640","journal-title":"Br J Cancer"},{"key":"5405_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S et al (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 6:8","journal-title":"J Immunother Cancer"},{"key":"5405_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.668731","volume":"11","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Gaggar S et al (2021) Cancer-associated fibroblasts and tumor-associated macrophages in cancer and cancer immunotherapy. Front Oncol 11:668731","journal-title":"Front Oncol"},{"key":"5405_CR35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2326-6066.CIR-16-0391","volume":"5","author":"T Noguchi","year":"2017","unstructured":"Noguchi T, Ward JP, Gubin MM et al (2017) Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol Res 5:106\u2013117","journal-title":"Cancer Immunol Res"},{"key":"5405_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216038","volume":"555","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang Y, Gao P et al (2023) Immune checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer Lett 555:216038","journal-title":"Cancer Lett"},{"key":"5405_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1285343","volume":"14","author":"K Liu","year":"2023","unstructured":"Liu K, Yuan S, Wang C et al (2023) Resistance to immune checkpoint inhibitors in gastric cancer. Front Pharmacol 14:1285343","journal-title":"Front Pharmacol"},{"key":"5405_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3604","volume":"9","author":"SP Arlauckas","year":"2017","unstructured":"Arlauckas SP, Garris CS, Kohler RH et al (2017) In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 9:eaal3604","journal-title":"Sci Transl Med"},{"key":"5405_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01786-6","volume":"40","author":"W Fang","year":"2021","unstructured":"Fang W, Zhou T, Shi H et al (2021) Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8(+) T cell exclusion. J Exp Clin Cancer Res 40:4","journal-title":"J Exp Clin Cancer Res"},{"key":"5405_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/cas.14272","volume":"111","author":"T Shima","year":"2020","unstructured":"Shima T, Shimoda M, Shigenobu T et al (2020) Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma. Cancer Sci 111:727\u2013738","journal-title":"Cancer Sci"},{"key":"5405_CR41","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/0008-5472.CAN-18-3208","volume":"79","author":"H Xiong","year":"2019","unstructured":"Xiong H, Mittman S, Rodriguez R et al (2019) Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment. Cancer Res 79:1493\u20131506","journal-title":"Cancer Res"},{"key":"5405_CR42","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1158\/1078-0432.CCR-19-4110","volume":"26","author":"G Rao","year":"2020","unstructured":"Rao G, Latha K, Ott M et al (2020) Anti-PD-1 induces M1 polarization in the glioma microenvironment and exerts therapeutic efficacy in the absence of CD8 cytotoxic T cells. Clin Cancer Res 26:4699\u20134712","journal-title":"Clin Cancer Res"},{"key":"5405_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010196","volume":"16","author":"M Yerolatsite","year":"2023","unstructured":"Yerolatsite M, Torounidou N, Gogadis A et al (2023) TAMs and PD-1 networking in gastric cancer: a review of the literature. Cancers 16:196","journal-title":"Cancers"},{"key":"5405_CR44","doi-asserted-by":"publisher","first-page":"9332","DOI":"10.7150\/thno.47137","volume":"10","author":"X Dai","year":"2020","unstructured":"Dai X, Lu L, Deng S et al (2020) Usp7 targeting modulates anti-tumor immune response by reprogramming tumor-associated macrophages in lung cancer. Theranostics 10:9332\u20139347","journal-title":"Theranostics"},{"key":"5405_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1062-7","volume":"18","author":"A Lin","year":"2019","unstructured":"Lin A, Wei T, Meng H et al (2019) Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer 18:139","journal-title":"Mol Cancer"},{"key":"5405_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000498","volume":"4","author":"AS Berghoff","year":"2019","unstructured":"Berghoff AS, Bellosillo B, Caux C et al (2019) Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. ESMO Open 4:e000498","journal-title":"ESMO Open"},{"key":"5405_CR47","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.7150\/thno.52435","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Gao A, Zhang F et al (2021) Ilt4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Theranostics 11:3392\u20133416","journal-title":"Theranostics"},{"key":"5405_CR48","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A et al (2019) Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol 16:361\u2013375","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5405_CR49","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1007\/s00262-023-03520-5","volume":"72","author":"KX Lin","year":"2023","unstructured":"Lin KX, Istl AC, Quan D et al (2023) PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunol Immunother 72:3875\u20133893","journal-title":"Cancer Immunol Immunother"},{"key":"5405_CR50","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka S, Hara H, Takahashi N et al (2020) Regorafenib plus Nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol 38:2053\u20132061","journal-title":"J Clin Oncol"},{"key":"5405_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194906","volume":"13","author":"CW Kim","year":"2021","unstructured":"Kim CW, Chon HJ, Kim C (2021) Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer. Cancers 13:4906","journal-title":"Cancers"},{"key":"5405_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009160","volume":"12","author":"BC O\u2019Connell","year":"2024","unstructured":"O\u2019Connell BC, Hubbard C, Zizlsperger N et al (2024) Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J Immunother Cancer 12:e009160","journal-title":"J Immunother Cancer"},{"key":"5405_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.0105-2896.2006.00419.x","volume":"212","author":"DM Sansom","year":"2006","unstructured":"Sansom DM, Walker LS (2006) The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev 212:131\u2013148","journal-title":"Immunol Rev"},{"key":"5405_CR54","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood-2019-122535","volume":"134","author":"SS Patel","year":"2019","unstructured":"Patel SS, Weirather JL, Lipschitz M et al (2019) The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative. Blood 134:2059\u20132069","journal-title":"Blood"},{"key":"5405_CR55","volume":"25","author":"L Michel","year":"2019","unstructured":"Michel L, Rassaf T, Totzeck M (2019) Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc 25:100420","journal-title":"Int J Cardiol Heart Vasc"},{"key":"5405_CR56","doi-asserted-by":"publisher","first-page":"25658","DOI":"10.18632\/aging.104175","volume":"12","author":"Z Huang","year":"2020","unstructured":"Huang Z, Yao F, Liu J et al (2020) Up-regulation of circRNA-0003528 promotes mycobacterium tuberculosis associated macrophage polarization via down-regulating miR-224-5p, miR-324-5p and miR-488-5p and up-regulating CTLA4. Aging 12:25658\u201325672","journal-title":"Aging"},{"key":"5405_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj1270","volume":"14","author":"MA Stanczak","year":"2022","unstructured":"Stanczak MA, Rodrigues Mantuano N, Kirchhammer N et al (2022) Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Sci Transl Med 14:eabj1270","journal-title":"Sci Transl Med"},{"key":"5405_CR58","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41388-021-02170-0","volume":"41","author":"KY Fjaestad","year":"2022","unstructured":"Fjaestad KY, Romer AMA, Goitea V et al (2022) Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment. Oncogene 41:1364\u20131375","journal-title":"Oncogene"},{"key":"5405_CR59","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nri727","volume":"2","author":"AH Sharpe","year":"2002","unstructured":"Sharpe AH, Freeman GJ (2002) The B7-CD28 superfamily. Nat Rev Immunol 2:116\u2013126","journal-title":"Nat Rev Immunol"},{"key":"5405_CR60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231263","author":"N Sharma","year":"2024","unstructured":"Sharma N, Fan X, Atolagbe OT et al (2024) ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20231263","journal-title":"J Exp Med"},{"key":"5405_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/imr.12521","volume":"276","author":"M Janakiram","year":"2017","unstructured":"Janakiram M, Shah UA, Liu W et al (2017) The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7\u2013H3. Immunol Rev 276:26\u201339","journal-title":"Immunol Rev"},{"key":"5405_CR62","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","volume":"31","author":"S Seaman","year":"2017","unstructured":"Seaman S, Zhu Z, Saha S et al (2017) Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature. Cancer Cell 31:501\u2013515","journal-title":"Cancer Cell"},{"key":"5405_CR63","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/modpathol.2010.95","volume":"23","author":"X Zang","year":"2010","unstructured":"Zang X, Sullivan PS, Soslow RA et al (2010) Tumor associated endothelial expression of B7\u2013H3 predicts survival in ovarian carcinomas. Mod Pathol 23:1104\u20131112","journal-title":"Mod Pathol"},{"key":"5405_CR64","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1002\/2211-5463.13280","volume":"11","author":"J Xie","year":"2021","unstructured":"Xie J, Sun M, Zhang D et al (2021) Fibronectin enhances tumor metastasis through B7\u2013H3 in clear cell renal cell carcinoma. FEBS Open Bio 11:2977\u20132987","journal-title":"FEBS Open Bio"},{"key":"5405_CR65","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s41375-018-0331-6","volume":"33","author":"L Lin","year":"2019","unstructured":"Lin L, Cao L, Liu Y et al (2019) B7\u2013H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src\/STAT3 and c-Cbl-mediated degradation of SOCS3. Leukemia 33:1475\u20131486","journal-title":"Leukemia"},{"key":"5405_CR66","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1158\/1535-7163.MCT-11-0072","volume":"10","author":"H Liu","year":"2011","unstructured":"Liu H, Tekle C, Chen YW et al (2011) B7\u2013H3 silencing increases paclitaxel sensitivity by abrogating Jak2\/Stat3 phosphorylation. Mol Cancer Ther 10:960\u2013971","journal-title":"Mol Cancer Ther"},{"key":"5405_CR67","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1002\/ijc.26238","volume":"130","author":"C Tekle","year":"2012","unstructured":"Tekle C, Nygren MK, Chen YW et al (2012) B7\u2013H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer 130:2282\u20132290","journal-title":"Int J Cancer"},{"key":"5405_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114890","volume":"163","author":"K Mortezaee","year":"2023","unstructured":"Mortezaee K (2023) B7\u2013H3 immunoregulatory roles in cancer. Biomed Pharmacother 163:114890","journal-title":"Biomed Pharmacother"},{"key":"5405_CR69","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","volume":"22","author":"E Picarda","year":"2016","unstructured":"Picarda E, Ohaegbulam KC, Zang X (2016) Molecular pathways: targeting B7\u2013H3 (CD276) for human cancer immunotherapy. Clin Cancer Res 22:3425\u20133431","journal-title":"Clin Cancer Res"},{"key":"5405_CR70","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/85339","volume":"2","author":"AI Chapoval","year":"2001","unstructured":"Chapoval AI, Ni J, Lau JS et al (2001) B7\u2013H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2:269\u2013274","journal-title":"Nat Immunol"},{"key":"5405_CR71","doi-asserted-by":"publisher","first-page":"12640","DOI":"10.1073\/pnas.0405025101","volume":"101","author":"R Castriconi","year":"2004","unstructured":"Castriconi R, Dondero A, Augugliaro R et al (2004) Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA 101:12640\u201312645","journal-title":"Proc Natl Acad Sci USA"},{"key":"5405_CR72","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/ITT.S507522","volume":"14","author":"Y Guo","year":"2025","unstructured":"Guo Y, Wang X, Zhang C et al (2025) Tumor immunotherapy targeting B7\u2013H3: from mechanisms to clinical applications. Immunotargets Ther 14:291\u2013320","journal-title":"Immunotargets Ther"},{"key":"5405_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114298","volume":"183","author":"N Cheng","year":"2021","unstructured":"Cheng N, Bei Y, Song Y et al (2021) B7\u2013H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy. Biochem Pharmacol 183:114298","journal-title":"Biochem Pharmacol"},{"key":"5405_CR74","first-page":"6177","volume":"14","author":"Y Mao","year":"2017","unstructured":"Mao Y, Chen L, Wang F et al (2017) Cancer cell-expressed B7\u2013H3 regulates the differentiation of tumor-associated macrophages in human colorectal carcinoma. Oncol Lett 14:6177\u20136183","journal-title":"Oncol Lett"},{"key":"5405_CR75","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3892\/or.2014.3587","volume":"33","author":"FB Kang","year":"2015","unstructured":"Kang FB, Wang L, Li D et al (2015) Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7\u2013H3 expression. Oncol Rep 33:274\u2013282","journal-title":"Oncol Rep"},{"key":"5405_CR76","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2326-6066.CIR-21-0407","volume":"10","author":"T Miyamoto","year":"2022","unstructured":"Miyamoto T, Murakami R, Hamanishi J et al (2022) B7\u2013H3 suppresses antitumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression. Cancer Immunol Res 10:56\u201369","journal-title":"Cancer Immunol Res"},{"key":"5405_CR77","doi-asserted-by":"publisher","first-page":"10388","DOI":"10.1073\/pnas.1434299100","volume":"100","author":"X Zang","year":"2003","unstructured":"Zang X, Loke P, Kim J et al (2003) B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 100:10388\u201310392","journal-title":"Proc Natl Acad Sci USA"},{"key":"5405_CR78","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000505756","volume":"87","author":"NI Kim","year":"2020","unstructured":"Kim NI, Park MH, Kweon SS et al (2020) B7\u2013H3 and B7\u2013H4 expression in breast cancer and their association with clinicopathological variables and T cell infiltration. Pathobiology 87:179\u2013192","journal-title":"Pathobiology"},{"key":"5405_CR79","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1158\/0008-5472.CAN-12-3457","volume":"73","author":"D Dangaj","year":"2013","unstructured":"Dangaj D, Lanitis E, Zhao A et al (2013) Novel recombinant human b7\u2013h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res 73:4820\u20134829","journal-title":"Cancer Res"},{"key":"5405_CR80","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3892\/mmr.2016.5510","volume":"14","author":"L Liu","year":"2016","unstructured":"Liu L, Li D, Chen S et al (2016) B7\u2013H4 expression in human infiltrating ductal carcinoma-associated macrophages. Mol Med Rep 14:2135\u20132142","journal-title":"Mol Med Rep"},{"key":"5405_CR81","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/j.joms.2022.03.019","volume":"80","author":"J Chi","year":"2022","unstructured":"Chi J, Liu Y, Yang L et al (2022) Silencing of B7H4 represses the development of oral squamous cell carcinoma through promotion of M1 macrophage polarization. J Oral Maxillofac Surg 80:1408\u20131423","journal-title":"J Oral Maxillofac Surg"},{"key":"5405_CR82","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1084\/jem.20100619","volume":"208","author":"L Wang","year":"2011","unstructured":"Wang L, Rubinstein R, Lines JL et al (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 208:577\u2013592","journal-title":"J Exp Med"},{"key":"5405_CR83","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1469594","volume":"7","author":"L Wang","year":"2018","unstructured":"Wang L, Jia B, Claxton DF et al (2018) VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. Oncoimmunology 7:e1469594","journal-title":"Oncoimmunology"},{"key":"5405_CR84","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm.4308","volume":"23","author":"J Gao","year":"2017","unstructured":"Gao J, Ward JF, Pettaway CA et al (2017) VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23:551\u2013555","journal-title":"Nat Med"},{"key":"5405_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112365","volume":"136","author":"S Jin","year":"2024","unstructured":"Jin S, Liu W, He X et al (2024) VISTA deficiency exerts anti-tumor effects in breast cancer through regulating macrophage polarization. Int Immunopharmacol 136:112365","journal-title":"Int Immunopharmacol"},{"key":"5405_CR86","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40164-024-00501-x","volume":"13","author":"Y Lin","year":"2024","unstructured":"Lin Y, Choukrani G, Dubbel L et al (2024) VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses. Exp Hematol Oncol 13:35","journal-title":"Exp Hematol Oncol"},{"key":"5405_CR87","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1006\/geno.1999.5877","volume":"59","author":"DL Mager","year":"1999","unstructured":"Mager DL, Hunter DG, Schertzer M et al (1999) Endogenous retroviruses provide the primary polyadenylation signal for two new human genes (HHLA2 and HHLA3). Genomics 59:255\u2013263","journal-title":"Genomics"},{"key":"5405_CR88","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1158\/1078-0432.CCR-14-2658","volume":"21","author":"Y Xiao","year":"2015","unstructured":"Xiao Y, Freeman GJ (2015) A new B7:CD28 family checkpoint target for cancer immunotherapy: HHLA2. Clin Cancer Res 21:2201\u20132203","journal-title":"Clin Cancer Res"},{"key":"5405_CR89","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/cells13100794","volume":"13","author":"A Kula","year":"2024","unstructured":"Kula A, Koszewska D, Kot A et al (2024) The importance of HHLA2 in solid tumors-a review of the literature. Cells 13:794","journal-title":"Cells"},{"key":"5405_CR90","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/2326-6066.CIR-20-0315","volume":"9","author":"RS Bhatt","year":"2021","unstructured":"Bhatt RS, Berjis A, Konge JC et al (2021) KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1. Cancer Immunol Res 9:156\u2013169","journal-title":"Cancer Immunol Res"},{"key":"5405_CR91","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1026534","volume":"4","author":"M Janakiram","year":"2015","unstructured":"Janakiram M, Chinai JM, Zhao A et al (2015) HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. Oncoimmunology 4:e1026534","journal-title":"Oncoimmunology"},{"issue":"61","key":"5405_CR92","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf9792","volume":"6","author":"Y Wei","year":"2021","unstructured":"Wei Y, Ren X, Galbo PM Jr. et al (2021) KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Sci Immunol 6(61):eabf9792","journal-title":"Sci Immunol"},{"key":"5405_CR93","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1038\/ncomms3043","volume":"4","author":"Y Zhu","year":"2013","unstructured":"Zhu Y, Yao S, Iliopoulou BP et al (2013) B7\u2013H5 costimulates human T cells via CD28H. Nat Commun 4:2043","journal-title":"Nat Commun"},{"key":"5405_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.153911","volume":"234","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Chen J, Liu Y et al (2022) Prognostic values of B7\u2013H3, B7\u2013H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis. Pathol Res Pract 234:153911","journal-title":"Pathol Res Pract"},{"key":"5405_CR95","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s10753-021-01547-3","volume":"45","author":"R Wang","year":"2022","unstructured":"Wang R, Guo H, Tang X et al (2022) Interferon gamma-induced interferon regulatory factor 1 activates transcription of HHLA2 and induces immune escape of hepatocellular carcinoma cells. Inflammation 45:308\u2013330","journal-title":"Inflammation"},{"key":"5405_CR96","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s10753-022-01644-x","volume":"45","author":"H Guo","year":"2022","unstructured":"Guo H, Zhang C, Tang X et al (2022) HHLA2 activates the JAK\/STAT signaling pathway by binding to TMIGD2 in hepatocellular carcinoma cells. Inflammation 45:1585\u20131599","journal-title":"Inflammation"},{"key":"5405_CR97","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1002\/cam4.4081","volume":"10","author":"W Sun","year":"2021","unstructured":"Sun W, Li S, Tang G et al (2021) HHLA2 deficiency inhibits non-small cell lung cancer progression and THP-1 macrophage M2 polarization. Cancer Med 10:5256\u20135269","journal-title":"Cancer Med"},{"key":"5405_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104609","volume":"152","author":"R Roskoski Jr","year":"2020","unstructured":"Roskoski R Jr (2020) Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res 152:104609","journal-title":"Pharmacol Res"},{"key":"5405_CR99","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA et al (2014) CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74:5057\u20135069","journal-title":"Cancer Res"},{"key":"5405_CR100","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/cac2.12420","volume":"43","author":"Z Wen","year":"2023","unstructured":"Wen Z, Sun H, Zhang Z et al (2023) High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway. Cancer Commun 43:562\u2013581","journal-title":"Cancer Commun"},{"key":"5405_CR101","doi-asserted-by":"publisher","first-page":"6854","DOI":"10.1021\/acs.jmedchem.4c00508","volume":"67","author":"Q Lv","year":"2024","unstructured":"Lv Q, Yang H, Wang D et al (2024) Discovery of a novel CSF-1R inhibitor with highly improved pharmacokinetic profiles and superior efficacy in colorectal cancer immunotherapy. J Med Chem 67:6854\u20136879","journal-title":"J Med Chem"},{"key":"5405_CR102","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1073\/pnas.1910856117","volume":"117","author":"JA Flores-Toro","year":"2020","unstructured":"Flores-Toro JA, Luo D, Gopinath A et al (2020) Ccr2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc Natl Acad Sci USA 117:1129\u20131138","journal-title":"Proc Natl Acad Sci USA"},{"key":"5405_CR103","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1007\/s10238-023-01227-6","volume":"23","author":"S Heller","year":"2023","unstructured":"Heller S, Glaeske S, Gluske K et al (2023) Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses. Clin Exp Med 23:5445\u20135461","journal-title":"Clin Exp Med"},{"key":"5405_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-01441-y","volume":"3","author":"MM Tu","year":"2020","unstructured":"Tu MM, Abdel-Hafiz HA, Jones RT et al (2020) Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. Commun Biol 3:720","journal-title":"Commun Biol"},{"key":"5405_CR105","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ymthe.2018.11.010","volume":"27","author":"G Shi","year":"2019","unstructured":"Shi G, Yang Q, Zhang Y et al (2019) Modulating the tumor microenvironment via oncolytic viruses and CSF-1R inhibition synergistically enhances anti-PD-1 immunotherapy. Mol Ther 27:244\u2013260","journal-title":"Mol Ther"},{"key":"5405_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194821","volume":"14","author":"Y Jeon","year":"2022","unstructured":"Jeon Y, Kang H, Yang Y et al (2022) A novel selective Axl\/Mer\/CSF1R kinase inhibitor as a cancer immunotherapeutic agent targeting both immune and tumor cells in the tumor microenvironment. Cancers 14:4821","journal-title":"Cancers"},{"key":"5405_CR107","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/carcin\/bgac043","volume":"43","author":"AN Omstead","year":"2022","unstructured":"Omstead AN, Paskewicz M, Gorbunova A et al (2022) CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model. Carcinogenesis 43:842\u2013850","journal-title":"Carcinogenesis"},{"key":"5405_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00089","volume":"11","author":"X Li","year":"2020","unstructured":"Li X, Fu Y, Yang B et al (2020) Brd4 inhibition by AZD5153 promotes antitumor immunity via depolarizing M2 macrophages. Front Immunol 11:89","journal-title":"Front Immunol"},{"key":"5405_CR109","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1136\/gutjnl-2022-329147","volume":"72","author":"Y Li","year":"2023","unstructured":"Li Y, Shen Z, Chai Z et al (2023) Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity. Gut 72:2307\u20132320","journal-title":"Gut"},{"key":"5405_CR110","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12915-021-01034-z","volume":"19","author":"YW Lim","year":"2021","unstructured":"Lim YW, Coles GL, Sandhu SK et al (2021) Single-cell transcriptomics reveals the effect of PD-L1\/TGF-beta blockade on the tumor microenvironment. BMC Biol 19:107","journal-title":"BMC Biol"},{"key":"5405_CR111","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","volume":"25","author":"DB Doroshow","year":"2019","unstructured":"Doroshow DB, Sanmamed MF, Hastings K et al (2019) Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res 25:4592\u20134602","journal-title":"Clin Cancer Res"},{"key":"5405_CR112","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389:67\u201376","journal-title":"Lancet"},{"key":"5405_CR113","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1038\/onc.2011.395","volume":"31","author":"Y Chen","year":"2012","unstructured":"Chen Y, Yang D, Li S et al (2012) Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma. Oncogene 31:2140\u20132152","journal-title":"Oncogene"},{"key":"5405_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110171","volume":"37","author":"X Geeraerts","year":"2021","unstructured":"Geeraerts X, Fernandez-Garcia J, Hartmann FJ et al (2021) Macrophages are metabolically heterogeneous within the tumor microenvironment. Cell Rep 37:110171","journal-title":"Cell Rep"},{"key":"5405_CR115","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 19:369\u2013382 (2019)","journal-title":"Nat Rev Immunol"},{"key":"5405_CR116","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng S, Li Z, Gao R et al (2021) A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184:792\u2013809","journal-title":"Cell"},{"key":"5405_CR117","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.immuni.2021.07.007","volume":"54","author":"K Mulder","year":"2021","unstructured":"Mulder K, Patel AA, Kong WT et al (2021) Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity 54:1883\u20131900","journal-title":"Immunity"},{"key":"5405_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216610","volume":"584","author":"S Yang","year":"2024","unstructured":"Yang S, Wang M, Hua Y et al (2024) Advanced insights on tumor-associated macrophages revealed by single-cell RNA sequencing: the intratumor heterogeneity, functional phenotypes, and cellular interactions. Cancer Lett 584:216610","journal-title":"Cancer Lett"},{"key":"5405_CR119","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ccell.2023.02.009","volume":"41","author":"L van Vlerken-Ysla","year":"2023","unstructured":"van Vlerken-Ysla L, Tyurina YY, Kagan VE et al (2023) Functional states of myeloid cells in cancer. Cancer Cell 41:490\u2013504","journal-title":"Cancer Cell"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05405-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-025-05405-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05405-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T11:03:12Z","timestamp":1771066992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-025-05405-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["5405"],"URL":"https:\/\/doi.org\/10.1007\/s11010-025-05405-w","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}